ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan
· Delayed Price · Currency is TWD 79.50
+2.20 (2.85%)
Aug 15, 2025, 1:59 PM CST
ACRO Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 44.23 | 51.06 | 27.63 | 21.83 | 18.03 | Upgrade
|
| Revenue Growth (YoY) | -13.38% | 84.79% | 26.59% | 21.04% | 146.35% | Upgrade
|
| Cost of Revenue | 18.04 | 11.95 | 14.21 | 7.29 | 9.46 | Upgrade
|
| Gross Profit | 26.19 | 39.12 | 13.43 | 14.54 | 8.58 | Upgrade
|
| Selling, General & Admin | 66.97 | 55.59 | 48.36 | 42.05 | 32.84 | Upgrade
|
| Research & Development | 25.72 | 28.64 | 27.85 | 26.04 | 31.7 | Upgrade
|
| Operating Expenses | 90.84 | 87.79 | 76.2 | 68.1 | 64.54 | Upgrade
|
| Operating Income | -64.65 | -48.67 | -62.78 | -53.55 | -55.97 | Upgrade
|
| Interest Expense | -0.29 | -0.26 | -0.1 | -0.09 | -0.1 | Upgrade
|
| Interest & Investment Income | 4.35 | 2.33 | 0.8 | 0.32 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.19 | -0.24 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.19 | 2.65 | 1.2 | 2.55 | 5.84 | Upgrade
|
| EBT Excluding Unusual Items | -60.59 | -44.19 | -60.88 | -50.78 | -50.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.33 | 2.77 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.15 | - | - | - | - | Upgrade
|
| Pretax Income | -62.07 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade
|
| Income Tax Expense | 0.02 | - | - | - | - | Upgrade
|
| Net Income | -62.09 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade
|
| Net Income to Common | -62.09 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 53 | 47 | 36 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 53 | 47 | 36 | 30 | Upgrade
|
| Shares Change (YoY) | 16.17% | 11.65% | 32.92% | 17.13% | 20.39% | Upgrade
|
| EPS (Basic) | -1.01 | -0.79 | -1.29 | -1.43 | -1.65 | Upgrade
|
| EPS (Diluted) | -1.01 | -0.79 | -1.29 | -1.43 | -1.65 | Upgrade
|
| Free Cash Flow | -73.93 | -69.27 | -49.45 | -48.2 | -33.45 | Upgrade
|
| Free Cash Flow Per Share | -1.21 | -1.31 | -1.05 | -1.36 | -1.10 | Upgrade
|
| Gross Margin | 59.21% | 76.60% | 48.59% | 66.62% | 47.55% | Upgrade
|
| Operating Margin | -146.17% | -95.31% | -227.17% | -245.34% | -310.35% | Upgrade
|
| Profit Margin | -140.37% | -81.11% | -220.33% | -232.61% | -277.37% | Upgrade
|
| Free Cash Flow Margin | -167.13% | -135.66% | -178.94% | -220.80% | -185.50% | Upgrade
|
| EBITDA | -58.18 | -43.75 | -53.56 | -44.05 | -43.43 | Upgrade
|
| EBITDA Margin | -131.54% | -85.69% | -193.84% | -201.80% | -240.84% | Upgrade
|
| D&A For EBITDA | 6.47 | 4.92 | 9.21 | 9.51 | 12.54 | Upgrade
|
| EBIT | -64.65 | -48.67 | -62.78 | -53.55 | -55.97 | Upgrade
|
| EBIT Margin | -146.17% | -95.31% | -227.17% | -245.34% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.